Anemia, a condition characterized by a decrease in the number of red blood cells or less than the normal quantity of hemoglobin in the blood, presents a diagnostic challenge due to its multifactorial etiologies. This guide aims to streamline the diagnostic approach to anemia for healthcare professionals.
A comprehensive history and physical examination form the cornerstone of anemia evaluation. Key information includes dietary habits, family history, and symptoms suggestive of bleeding. Physical examination should focus on signs of specific causes like pallor, jaundice, or splenomegaly.
Initial laboratory tests should include a complete blood count (CBC) and reticulocyte count. These tests provide valuable information about the size and hemoglobin content of the red blood cells, which is crucial for further classification of anemia.
Anemia can be classified as microcytic, normocytic, or macrocytic based on the mean corpuscular volume (MCV). Iron deficiency typically results in microcytic anemia, while vitamin B12 or folate deficiency results in macrocytic anemia. Normocytic anemia may be due to chronic disease, acute blood loss, or bone marrow failure.
Further tests should be guided by the initial findings. Iron studies, vitamin B12, and folate levels are useful for microcytic and macrocytic anemias. For normocytic anemia, the reticulocyte count helps distinguish between hypoproliferative and hyperproliferative states. In certain cases, bone marrow biopsy may be necessary.
Understanding the complexities of anemia diagnosis requires a systematic approach to history taking, physical examination, and laboratory investigation. By classifying anemia based on MCV and tailoring further investigations accordingly, healthcare professionals can efficiently diagnose and manage this common but multifaceted condition.
1.
Research discovery halts childhood brain tumor before it forms
2.
Increased Data Support Active Monitoring for Low-Risk Prostate Cancer.
3.
'CDC Must Be Investigated'; David Lynch, Bob Uecker Die; Nasal Epinephrine Warning
4.
Increasing Access to Prostate Cancer Drugs; Reducing Toxic Emissions; FTC Files a 'Charity' Suit.
5.
Infections the Main Cause of Nonrelapse Mortality After CAR-T for Blood Cancers
1.
Beyond the Blinders: A Review of Targeted Therapeutic Strategies for Triple-Negative Breast Cancer in 2025
2.
AI-Based Cancer Follow-Up Monitoring: Transforming Survivorship Care through Intelligent Surveillance
3.
Preventing Sarcopenia During Cancer Treatment
4.
Guidance for Managing Complex Anticoagulation
5.
Unlocking the Potential of Sarclisa: A New Hope for Cancer Treatment
1.
International Cancer Conference
2.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
3.
International Cancer Conference
4.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Updates on Standard V/S High Risk Myeloma Treatment
2.
Navigating the Complexities of Ph Negative ALL - Part XIV
3.
Current Scenario of Blood Cancer- A Conclusion on Genomic Testing & Advancement in Diagnosis and Treatment
4.
Advances in Classification/ Risk Stratification of Plasma Cell Dyscrasias
5.
Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part I
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation